ArticleCancer cytopathology2016
FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
Article in Cancer cytopathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.Gynecologic oncology · 2025Trial
- Comparative Analysis of Next-Generation Sequencing and Immunohistochemistry in MSI/MMR Testing.Turk patoloji dergisi · 2025Article
- Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing.Cancer cytopathology · 2023Article
- Biomarker testing of cytology specimens in personalized medicine for lung cancer patients.Journal of pathology and translational medicine · 2022Review
- Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.Cancer cytopathology · 2021Article
- Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer.Frontiers in medicine · 2021Review
- Diagnostic challenges in the gray-zone lesions of fine-needle aspiration cytology.CytoJournal · 2021Review
- Archival bone marrow smears are useful in targeted next-generation sequencing for diagnosing myeloid neoplasms.PloS one · 2021Article
- Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.Diagnostic pathology · 2020Article
- Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.Biomedical reports · 2019Article
- Article
- The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer.Annals of translational medicine · 2019Review
- The utilization of cytologic and small biopsy samples for ancillary molecular testing.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Review
- Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma.International journal of clinical and experimental pathology · 2018Article
- Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.International journal of cancer · 2017Article
- The use of endobronchial ultrasound guided transbronchial needle aspiration specimens for next generation sequencing in non-small cell lung cancer: a clinical perspective.Journal of thoracic disease · 2017Article
- Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors.Cancer medicine · 2016Article
- Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience.Archives of pathology & laboratory medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiff-Quik-stained fine-needle aspiration (FNA) smears and touch preparations from biopsies represent alternative specimens for molecular testing when cell block or biopsy material is insufficient. This study describes the use of these samples for targeted next-generation sequencing (NGS) of primary and metastatic lung adenocarcinoma and reports the DNA quality and success rates of FNA smears versus other specimens from 1 year of clinical use.
methodsA validation set of 10 slides from 9 patients with prior clinical epidermal growth factor receptor (EGFR) Sanger sequencing and KRAS pyrosequencing (5 KRAS-positive/EGFR-negative and 4 KRAS-negative/EGFR-negative) underwent DNA extraction, quality assessment, and targeted NGS. Subsequently, lung adenocarcinoma specimens submitted for NGS solid tumor mutation panel testing in 1 calendar year (60 biopsies, 57 resections, 33 FNA cell blocks, 12 FNA smears, and 10 body fluid cell blocks) were reviewed for specimen adequacy, sequencing success, and DNA quality.
resultsAll 10 validation samples met the DNA quality threshold (delta Ct threshold < 8; range, -2.2 to 4.9) and yielded 0.5 to 22 μg of DNA. The KRAS and EGFR mutation status from FNA smears according to NGS was concordant with previous clinical testing for all 10 samples. In the 1-year review, FNA smears were 100% successful, and this suggested a performance equivalent to or better than the performance of established specimen types, including FNA cell blocks. DNA quality according to ΔCt was significantly better with FNA smears versus biopsies, resections, and FNA cell blocks.
conclusionsFNA smears of lung adenocarcinomas are high-quality alternative specimens for a targeted NGS panel with a high success rate in clinical practice. Cancer Cytopathol 2016;124:406-14. © 2016 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.